Semaglutide weight loss outcomes in STEP-1 trial
New England Journal of Medicine
2021
Study summary
Semaglutide was studied for obesity treatment in non-diabetic adults.
Peptides studied
Goals studied
Stack studied
Metabolic Stack
Key findings
Participants achieved substantial weight loss relative to placebo.
Study details
Study type
randomized clinical trial
Journal
New England Journal of Medicine
DOI / PubMed
10.1056/NEJMoa2032183
Year
2021
Explore peptide profiles
Discover compounds, understand their mechanisms, and explore the research behind each peptide.
